DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Contribución de congreso (ConferenceOutput)
Efficient blocking of Sars-CoV-2 entry through tryptophan derivatives interfering with the interaction of Ace2 with the viral spike
Resumen del póster presentado al International Symposium on Medicinal Chemistry, celebrado en Niza (Francia) del 4 al 8 de septiembre de 2022., The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the largest pandemic the
world has suffered in recent years, COVID-19.1 Coronaviruses are characterized by spike proteins that are
crucial for the entry process into the host cells. Particularly, the spike protein of SARS-CoV-2 binds to the
human angiotensin converting enzyme 2 (ACE2) through its receptor binding domain (RBD) (Figure 1), leading
to viral entry and subsequent infection of the host cell.1,2 Thus, inhibition of SARS-CoV-2 by blocking the
interaction of the spike protein with ACE2 represents an appealing antiviral strategy that can be combined with
the treatments already approved. Our research group has been extensively involved in the search for entry inhibitors of different virus, as recently
reported for potent HIV and EV-A71 antivirals.3 In the current project, 200 compounds were evaluated as entry
inhibitors in a HTS assay using VSV pseudoparticles expressing the SARS-CoV-2 spike protein in Vero cells.
The identified hits, with a tryptophan scaffold, have been further explored through the synthesis of structural
analogues. As a result, we have identified compounds able to block viral entry in the pseudoparticles assay with
IC50 values in the low micromolar or submicromolar range and in the absence of toxicity to host cells (CC50>100
µM). Moreover, their antiviral activity has been confirmed against SARS-CoV-2 in Vero E6 and A549-ACE2
cells. Additionally, biophysical studies using microscale thermophoresis have evidenced that these compounds
are able to interact with the RBD and spike of SARS-CoV-2 and significantly affect the KD of the interaction of
the RBD with ACE2. Thus, these compounds represent an interesting alternative for the development of
SARS-CoV-2 therapies and/or prevention., This research has been funded by Fondo Supera COVID-19 (Crue-CSIC-Santander), by the European Commission – NextGenerationEU (Regulation EU 2020/2094), through CSIC's Global Health Platform (PTI Salud Global) and by PID2019-105117RR-C22/ AEI / 10.13039/501100011033., No